In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of:ATLAS and FLAIR studies of long-acting injectable CAB + RPVATLAS 2M dosing studyFDA approval and DHHS statement on use of long-acting injectable ARTStudies on whether an oral lead-in is neededPresenter:Daniel R. Kuritzkes, MDChief, Division of Infectious DiseasesBrigham and Women’s HospitalHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the slides at:https://bit.ly/3hNfHIISee the entire program at:https://bit.ly/2TXTYWx